Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CBX7 | O95931 | 3/20 | 0.61 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.61 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.61 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970176 | 0.86 | KMT2A (0.68) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL30808661 | 0.86 | KMT2A (0.68) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL4432608 | 0.85 | KMT2A (0.67) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL30808581 | 0.84 | ALDH1A1 (0.66) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL30336808 | 0.81 | HTT (0.47) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL29209149 | 0.81 | HTT (0.47) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL14046919 | 0.81 | TSHR (0.63) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL4968483 | 0.81 | ALDH1A1 (0.66) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL8225730 | 0.81 | KMT2A (0.61) | KMT2AMEN1TSHRPOLBLMNA | |
| SCHEMBL11982070 | 0.80 | TSHR (0.78) | KMT2AMEN1TSHRPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20210393674-A1 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE | AIR CROSS, INC | 2021-12-23 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180311499-A1 | Treatment of Dermatological Conditions via Neuromodulation | PALO ALTO INVESTORS | 2018-11-01 | — | — | US | disclosed |
| CN-108348894-A | Ozonolysis for compound activation and ozonolysis | 空气交叉股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-1093123-C | Lactams and imides of aralkyl and arylalkylene heterocycles | PFIZER (US) | 2002-10-23 | — | — | CN | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| CN-1329002-A | Intermediate product for preparing aralkyl and aryl alkylene heterocyclic lactam and imide | PFIZER (US) | 2002-01-02 | — | — | CN | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| CN-1231661-A | Lactams and imides of aralkyl and arylalkylene heterocycles | PFIZER (US) | 1999-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393674-A1 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE | DUOX1, DUOX2, AOX1 | KMT2A 3488/4885MEN1 3061/4885TSHR 3902/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | KMT2A 4411/4885MEN1 671/4885TSHR 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.